| Autoantibodies against type I IFNs in patients with life-threatening COVID-19 P Bastard, LB Rosen, Q Zhang, E Michailidis, HH Hoffmann, Y Zhang, ... Science 370 (6515), eabd4585, 2020 | 2456 | 2020 |
| Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Q Zhang, P Bastard, Z Liu, J Le Pen, M Moncada-Velez, J Chen, M Ogishi, ... Science 370 (6515), eabd4570, 2020 | 2142 | 2020 |
| Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ... Science immunology 6 (62), eabl4340, 2021 | 442 | 2021 |
| An immune-based biomarker signature is associated with mortality in COVID-19 patients MS Abers, OM Delmonte, EE Ricotta, J Fintzi, DL Fink, AAA de Jesus, ... JCI insight 6 (1), 2021 | 325 | 2021 |
| Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1 P Bastard, E Orlova, L Sozaeva, R Lévy, A James, MM Schmitt, S Ochoa, ... Journal of Experimental Medicine 218 (7), 2021 | 234 | 2021 |
| Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19 C Liu, AJ Martins, WW Lau, N Rachmaninoff, J Chen, L Imberti, ... Cell 184 (7), 1836-1857. e22, 2021 | 181 | 2021 |
| Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19 K Sacco, R Castagnoli, S Vakkilainen, C Liu, OM Delmonte, C Oguz, ... Nature medicine 28 (5), 1050-1062, 2022 | 180 | 2022 |
| Life-threatening COVID-19: defective interferons unleash excessive inflammation Q Zhang, P Bastard, A Bolze, E Jouanguy, SY Zhang, A Cobat, ... Med 1 (1), 14-20, 2020 | 140 | 2020 |
| The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies J Manry, P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, ... Proceedings of the National Academy of Sciences 119 (21), 2022 | 128 | 2022 |
| Neutralizing type‐I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID‐19 MS Abers, LB Rosen, OM Delmonte, E Shaw, P Bastard, L Imberti, ... Immunology and cell biology 99 (9), 917-921, 2021 | 82 | 2021 |
| Temporal dynamics of anti–type 1 interferon autoantibodies in patients with coronavirus disease 2019 ER Shaw, LB Rosen, A Cheng, K Dobbs, OM Delmonte, EMN Ferré, ... Clinical Infectious Diseases 75 (1), e1192-e1194, 2022 | 31 | 2022 |
| Virulence attenuating combination therapy: A potential multi-target synergy approach to treat Pseudomonas aeruginosa infections in cystic fibrosis patients E Shaw, WM Wuest RSC Medicinal Chemistry 11 (3), 358-369, 2020 | 26 | 2020 |
| SARS-CoV-2 spike protein-directed monoclonal antibodies may ameliorate COVID-19 complications in APECED patients EMN Ferré, MM Schmitt, S Ochoa, LB Rosen, ER Shaw, PD Burbelo, ... Frontiers in Immunology 12, 720205, 2021 | 19 | 2021 |
| Multi-omics approach identifies novel age-, time-and treatment-related immunopathological signatures in MIS-C and pediatric COVID-19 K Sacco, R Castagnoli, S Vakkilainen, C Liu, OM Delmonte, C Oguz, ... medRxiv, 2021.09. 24.21263853, 2021 | 7 | 2021 |
| Serological responses to human virome define clinical outcomes of Italian patients infected with SARS-CoV-2 L Wang, J Candia, L Ma, Y Zhao, L Imberti, A Sottini, E Quiros-Roldan, ... International Journal of Biological Sciences 18 (15), 5591, 2022 | 5 | 2022 |
| Chimeric autoantigen-T cell receptor (CATCR)-T cell therapies to selectively target autoreactive B cells BJ Mog, ER Shaw, MS Hwang, AH Pearlman, SR DiNapoli, S Paul, ... ARTHRITIS & RHEUMATOLOGY 74, 3337-3338, 2022 | 4 | 2022 |
| The influence of immune immaturity on outcome after virus infections ER Shaw, HC Su The Journal of Allergy and Clinical Immunology: In Practice 9 (2), 641-650, 2021 | 4 | 2021 |
| Type I Interferon Autoantibodies Are Detected in Those with Critical COVID-19, Including a Young Female Patient D Yee, M Tso, E Shaw, LB Rosen, E Samuels, P Bastard, JL Casanova, ... Open Forum Infectious Diseases 8 (Supplement_1), S325-S326, 2021 | 3 | 2021 |
| Transient Autoantibodies to Danger Signals ER Shaw, P Matzinger Frontiers in Immunology 14, 14, 2023 | 2 | 2023 |
| Detection of Neutralizing Anti‐Type 1 Interferon Autoantibodies ER Shaw, LB Rosen, L Ding, SM Holland, HC Su Current protocols 2 (8), e511, 2022 | 2 | 2022 |
